Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Net Margin (2016 - 2025)

Amicus Therapeutics filings provide 14 years of Net Margin readings, the most recent being 0.91% for Q4 2025.

  • On a quarterly basis, Net Margin fell 893.0% to 0.91% in Q4 2025 year-over-year; TTM through Dec 2025 was 4.27%, a 635.0% increase, with the full-year FY2025 number at 4.27%, up 635.0% from a year prior.
  • Net Margin hit 0.91% in Q4 2025 for Amicus Therapeutics, down from 10.24% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 10.24% in Q3 2025 to a low of 108.31% in Q1 2022.
  • Median Net Margin over the past 5 years was 42.3% (2022), compared with a mean of 42.48%.
  • Biggest five-year swings in Net Margin: surged 4807bps in 2021 and later plummeted -1082bps in 2022.
  • Amicus Therapeutics' Net Margin stood at 101.37% in 2021, then surged by 37bps to 63.41% in 2022, then soared by 54bps to 29.41% in 2023, then surged by 133bps to 9.85% in 2024, then crashed by -91bps to 0.91% in 2025.
  • The last three reported values for Net Margin were 0.91% (Q4 2025), 10.24% (Q3 2025), and 15.79% (Q2 2025) per Business Quant data.